Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies

Journal of Gastroenterology

Volumn 46, Issue 3, 2011, Pages 289-296

  Tanaka, Shinji ^a   Arii, Shigeki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Cancer stem cell; Hepatocellular carcinoma; Hypoxia; Niche

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; AZD 8055; BELINOSTAT; BEVACIZUMAB; BMS 907351; BRIVANIB; BRIVANIB ALANINATE; CEDIRANIB; CETUXIMAB; CIXUTUMUMAB; COMBRETASTATIN A1 PHOSPHATE; ERLOTINIB; EVEROLIMUS; FORETINIB; GEFITINIB; INTEDANIB; LAPATINIB; LINIFANIB; NEXABAR; PANOBINOSTAT; PAZOPANIB; RAMUCIRUMAB; RAPAMYCIN; REGORAFENIB; SELUMETINIB; SORAFENIB; SU 6688; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; XL 184;

ANGIOGENESIS; CANCER GROWTH; CANCER STEM CELL; CANCER SURVIVAL; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LIVER CELL CARCINOMA; MITOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANOXIA; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; STEM CELL NICHE;

EID: 79954417584     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0387-9     Document Type: Review

References (50)

1. S Arii Y Yamaoka S Futagawa, et al. 2000 Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan Hepatology 32 1224 1229 11093728 10.1053/jhep.2000.20456 1:STN:280: DC%2BD3M%2FntFegsQ%3D%3D
2. IB Weinstein 2002 Cancer. Addiction to oncogenes-the Achilles heel of cancer Science 297 63 64 12098689 10.1126/science.1073096 1:CAS:528: DC%2BD38XltFGgsbc%3D (Pubitemid 34743088)
3. S Tanaka S Arii 2009 Molecularly targeted therapy for hepatocellular carcinoma Cancer Sci 100 1 8 19038007 10.1111/j.1349-7006.2008.01006.x 1:CAS:528:DC%2BD1MXhtlGgurw%3D
4. JM Llovet J Bruix 2008 Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 1312 1327 18821591 10.1002/hep.22506 1:CAS:528:DC%2BD1cXht1Khu7zP
5. H Ishii M Iwatsuki K Ieta D Ohta N Haraguchi K Mimori M Mori 2008 Cancer stem cells and chemoradiation resistance Cancer Sci 99 1871 1877 19016744 10.1111/j.1349-7006.2008.00914.x 1:CAS:528:DC%2BD1cXhsVGlsbnF
6. D Hanahan J Folkman 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 353 364 8756718 10.1016/S0092-8674(00)80108-7 1:CAS:528:DyaK28XltVSks7s%3D (Pubitemid 26272076)
7. S Tanaka S Arii 2006 Current status of perspective of antiangiogenic therapy for cancer; hepatocellular carcinoma Int J Clin Oncol 11 82 89 16622743 10.1007/s10147-006-0566-5 1:CAS:528:DC%2BD28Xjs1Klsb8%3D
8. N Ferrara 2002 VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 795 803 12360282 10.1038/nrc909 1:CAS:528:DC%2BD38XnsVGrtbk%3D (Pubitemid 37328914)
9. M Mise S Arii H Higashituji, et al. 1996 Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor Hepatology 23 455 464 8617424 10.1002/hep.510230309 1:STN:280:DyaK283gs1Wjsw%3D%3D (Pubitemid 26087158)
10. J Andrae R Gallini C Betsholtz 2008 Role of platelet-derived growth factors in physiology and medicine Genes Dev 22 1276 1312 18483217 10.1101/gad.1653708 1:CAS:528:DC%2BD1cXmsVWmsbs%3D (Pubitemid 351717519)
11. F Kuhnert BY Tam B Sennino, et al. 2008 Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis Proc Natl Acad Sci USA 105 10185 10190 18632559 10.1073/pnas.0803194105 1:CAS:528:DC%2BD1cXptF2rtr0%3D
12. S Uematsu T Higashi K Nouso, et al. 2005 Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma J Gastroenterol Hepatol 20 583 588 15836707 10.1111/j.1440-1746.2005.03726.x 1:CAS:528:DC%2BD2MXls1aqt7g%3D (Pubitemid 40755271)
13. RT Poon IO Ng C Lau WC Yu ST Fan J Wong 2001 Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma Am J Surg 182 298 304 11587697 10.1016/S0002-9610(01)00708-5 1:CAS:528:DC%2BD3MXnt1Shtb0%3D (Pubitemid 32918381)
14. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 18650514 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D
15. S Faivre E Raymond E Boucher, et al. 2009 Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study Lancet Oncol 10 794 800 19586800 10.1016/S1470-2045(09)70171-8 1:CAS:528:DC%2BD1MXptlals70%3D
16. S Tanaka M Mori Y Sakamoto M Makuuchi K Sugimachi JR Wands 1999 Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma J Clin Invest 103 341 345 9927494 10.1172/JCI4891 1:CAS:528:DyaK1MXovVKnuw%3D%3D (Pubitemid 29069983)
17. S Tanaka JR Wands S Arii 2006 Induction of angiopoietin-2 gene expression by COX-2: a novel role for COX-2 inhibitors during hepatocarcinogenesis J Hepatol 44 233 235 16290311 10.1016/j.jhep.2005.09.012 1:CAS:528: DC%2BD2MXht12ktLvE (Pubitemid 41772539)
18. J Holash PC Maisonpierre D Compton P Boland CR Alexander D Zagzag GD Yancopoulos SJ Wiegand 1999 Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1994 1998 10373119 10.1126/science.284.5422.1994 1:CAS:528:DyaK1MXktVWntrY%3D (Pubitemid 29309448)
19. S Tanaka K Sugimachi Y Yamashita Yi T Ohga K Shirabe M Shimada JR Wands K Sugimachi 2002 Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma Hepatology 35 861 867 11915032 10.1053/jhep.2002.32535 1:CAS:528:DC%2BD38XjtFSksL4%3D (Pubitemid 34258380)
20. T Etoh H Inoue S Tanaka GF Bernard S Kitano M Mori 2001 Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases Cancer Res 61 2145 2153 11280779 1:CAS:528:DC%2BD3MXit1Ogsbo%3D (Pubitemid 32692040)
21. RS Herbst D Hong L Chap, et al. 2009 Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors J Clin Oncol 27 3557 3565 19546406 10.1200/JCO.2008.19.6683 1:CAS:528:DC%2BD1MXhtVSqtLjK
22. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011 (in press).
23. S Tanaka K Sugimachi S Maehara, et al. 2002 Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinoma Surgery 131 S142 S147 11821801 10.1067/msy.2002.119495 (Pubitemid 34118630)
24. PA Farazi RA DePinho 2006 Hepatocellular carcinoma pathogenesis: from genes to environment Nat Rev Cancer 6 674 687 16929323 10.1038/nrc1934 1:CAS:528:DC%2BD28XosVOmsLs%3D (Pubitemid 44286000)
25. S Tanaka S Arii 2010 Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science Int J Clin Oncol 15 235 241 20505971 10.1007/s10147-010-0083-4 1:CAS:528:DC%2BC3cXntlKkt7k%3D
26. S Tanaka S Arii M Yasen K Mogushi NT Su C Zhao, et al. 2008 Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy Br J Surg 95 611 619 18311747 10.1002/bjs.6011 1:CAS:528:DC%2BD1cXntFeit7s%3D
27. N Keen S Taylor 2004 Aurora-kinase inhibitors as anticancer agents Nat Rev Cancer 4 927 936 15573114 10.1038/nrc1502 1:CAS:528:DC%2BD2cXhtVarsLjN (Pubitemid 39626216)
28. A Aihara S Tanaka M Yasen, et al. 2010 The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma J Hepatol 52 63 71 19913935 10.1016/j.jhep.2009.10.013 1:CAS:528:DC%2BD1MXhsFagt7bO
29. S Loges M Mazzone P Hohensinner P Carmeliet 2009 Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited Cancer Cell 15 167 170 19249675 10.1016/j.ccr.2009.02.007 1:CAS:528:DC%2BD1MXltFSmtb0%3D
30. B Keith MC Simon 2007 Hypoxia-inducible factors, stem cells, and cancer Cell 129 465 472 17482542 10.1016/j.cell.2007.04.019 1:CAS:528: DC%2BD2sXlvVGktbw%3D (Pubitemid 46660978)
31. A Mohyeldin T Garzón-Muvdi A Quiñones-Hinojosa 2010 Oxygen in stem cell biology: a critical component of the stem cell niche Cell Stem Cell 7 150 161 20682444 10.1016/j.stem.2010.07.007 1:CAS:528:DC%2BC3cXhtVyrt77L
32. F Arai T Suda 2007 Maintenance of quiescent hematopoietic stem cells in the osteoblastic niche Ann NY Acad Sci 1106 41 53 17332071 10.1196/annals.1392. 005 1:CAS:528:DC%2BD2sXpt1yktbo%3D (Pubitemid 47443041)
33. H Iwasaki T Suda 2009 Cancer stem cells and their niche Cancer Sci 100 1166 1172 19432904 10.1111/j.1349-7006.2009.01177.x 1:CAS:528: DC%2BD1MXosl2ktL8%3D
34. C Calabrese H Poppleton M Kocak, et al. 2007 A perivascular niche for brain tumor stem cells Cancer Cell 11 69 82 17222791 10.1016/j.ccr.2006.11.020 1:CAS:528:DC%2BD2sXhtFClsLY%3D (Pubitemid 46054518)
35. P Cammareri A Scopelliti M Todaro, et al. 2010 Aurora-A is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells Cancer Res 70 4655 4665 20460511 10.1158/0008-5472.CAN-09-3953 1:CAS:528:DC%2BC3cXmslWgtb4%3D
36. N Haraguchi H Ishii K Mimori, et al. 2010 CD13 is a therapeutic target in human liver cancer stem cells J Clin Invest 120 3326 3339 20697159 10.1172/JCI42550 1:CAS:528:DC%2BC3cXhtFertbvI
37. 2 regulates stem cells through Wnt/β-catenin signalling. Nat Cell Biol. 2010;12:1007-13.
38. S Tanaka T Akiyoshi M Mori JR Wands K Sugimachi 1998 A novel frizzled gene identified in human esophageal carcinoma mediates APC/β-catenin signals Proc Natl Acad Sci USA 95 10164 10169 9707618 10.1073/pnas.95.17.10164 1:CAS:528:DyaK1cXlsFWlurw%3D (Pubitemid 28415312)
39. P Merle S De la Monte M Kim M Herrmann S Tanaka A Von Dem Bussche MC Kew C Trepo JR Wands 2004 Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma Gastroenterology 127 1110 1122 15480989 10.1053/j.gastro.2004.07.009 1:CAS:528:DC%2BD2cXpsVOit74%3D (Pubitemid 39345880)
40. A de La Coste B Romagnolo, et al. 1998 Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas Proc Natl Acad Sci USA 95 8847 8851 9671767 10.1073/pnas.95.15.8847 (Pubitemid 28350577)
41. S Satoh Y Daigo Y Furukawa, et al. 2000 Axin 1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of Axin 1 Nat Genet 24 245 250 10700176 10.1038/73448 1:CAS:528:DC%2BD3cXhvFaqtrY%3D (Pubitemid 30132191)
42. S Tanaka K Sugimachi T Kameyama S Maehara K Shirabe M Shimada JR Wands Y Maehara 2003 Human WISP1v, a member of CCN family, is associated with invasive cholangiocarcinoma Hepatology 37 1122 1129 12717393 10.1053/jhep.2003.50187 1:CAS:528:DC%2BD3sXktVWnsLg%3D (Pubitemid 36538689)
43. A Murakata S Tanaka K Mogushi, et al. 2011 Gene expression signature of the gross morphology in hepatocellular carcinoma Ann Surg 253 94 100 21233610 10.1097/SLA.0b013e3181f9bc00
44. SM Huang YM Mishina S Liu, et al. 2009 Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling Nature 461 614 620 19759537 10.1038/nature08356 1:CAS:528:DC%2BD1MXhtFentbzP
45. CA Thorne AJ Hanson J Schneider, et al. 2010 Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α Nat Chem Biol 6 829 836 20890287 10.1038/nchembio.453 1:CAS:528:DC%2BC3cXht1elu7zO
46. WG Kaelin Jr 2005 The concept of synthetic lethality in the context of anticancer therapy Nat Rev Cancer 5 689 698 16110319 10.1038/nrc1691 1:CAS:528:DC%2BD2MXpsleks7c%3D (Pubitemid 41486362)
47. T Dobzhansky 1946 Genetics of natural populations. XIII. Recombination and variability in populations of Drosophila pseudoobscura Genetics 31 269 290
48. J Luo MJ Emanuele D Li, et al. 2009 A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 137 835 848 19490893 10.1016/j.cell.2009.05.006 1:CAS:528:DC%2BD1MXosVCltb4%3D
49. PC Fong DS Boss TA Yap, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 123 134 19553641 10.1056/NEJMoa0900212 1:CAS:528:DC%2BD1MXosVKrtrw%3D
50. JD Iglehart DP Silver 2009 Synthetic lethality-a new direction in cancer-drug development N Engl J Med 361 189 191 19553640 10.1056/NEJMe0903044 1:CAS:528:DC%2BD1MXosVKqurk%3D